[PSMA向治疗转移性割抵抗性前列腺癌的治疗]
A Shapovalenko R1,2,3,4,5, D Shpikina A1,2,3,4,5, O Morozov A1,2,3,4,5
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Urologiia (Moscow, Russia : 1999)
|November 20, 2024
概括
用PSMA向治疗为转移性割抵抗性前列腺癌 (mCRPC) 提供了一种新方法. 这种治疗术策略使用向前列腺特异性膜抗原 (PSMA) 的放射性链体来进行有效的治疗.
科学领域:
- 在瘤学瘤学.
- 核医学就是核医学.
- 放射性药物疗法是一种放射性药物疗法.
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 存在重大治疗挑战.
- 前列腺特异性膜抗原 (PSMA) 向疗法是一种治疗方法,利用向PSMA的放射性连接体进行mCRPC治疗.
- 这种方法允许同时进行诊断和治疗,准表达PSMA的瘤细胞.
研究的目的:
- 审查目前利用PSMA和放射性核化物治疗mCRPC患者的方法.
- 突出PSMA向治疗晚期前列腺癌的原则和应用.
主要方法:
- 对针对mCRPC的PSMA向放射性干疗法的文献综述.
- 对不同放射性核素 (α和β减小发射体) 和它们的相关配体的分析.
- 对治疗疗效和毒性概况的评估.
主要成果:
- 贝塔减去放射性核酸治疗,特别是使用-177 (177Lu-PSMA-617和177Lu-PSMA-I&T),由于其"交叉火效应",较低的毒性和可用性而被优先考虑.
- 用actinium-225 (225Ac-PSMA) 治疗alpha-radionuclide提供了一个替代方案,虽然更有毒,对于那些耐受beta-minus治疗的患者来说.
结论:
- 基于177Lu的PSMA向治疗是对mCRPC的首选治疗方法.
- 基于225Ac的PSMA向治疗是有价值的二线或救援选择.
- 针对PSMA的天文学是管理mCRPC的一个重大进步.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.2K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K